Morning Overview on MSN
Trial: Sulthiame pill cut sleep apnea breathing interruptions by 50%
A once-daily pill called sulthiame cut breathing interruptions during sleep by up to 47 percent in adults with obstructive ...
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and ...
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
Elemento is the director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. Sternberg is the clinical director of the Englander Institute for Precision Medicine. Khozin is ...
In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, examines the most common threats to trial data reliability, including opaque methodologies, synthetic controls, and the limits of ...
In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, reflects on the gap between sponsor expectations and statistical reality, drawing on lessons from the COVID era to argue for more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results